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asic biotechnology has been around a long
time. Bakers have used yeast for centuries,
and smallpox vaccination was introduced in
the 18th century, long before the details of cell
structure were known. However, recent events, such as
the human genome project, have firmly anchored
biotechnology and its applications in the public’s mind
and imagination. Here, Tim Schiller briefly describes
major biotechnology products, reviews estimates of the
industry’s size and scope, and outlines where the industry
is most active in the United States, especially in the
Third District states of Pennsylvania, New Jersey, and
Delaware.
Biotechnology uses living
organisms at the cellular or molecular
level for medical, agricultural, or
industrial purposes. The publication of
the human genome sequence in 2001
brought biotechnology dramatically
before the public as a leading-edge
scientific endeavor. Although biotech-
nology has only relatively recently
gained widespread public interest, basic
biotechnology is thousands of years old.
This article briefly describes
major biotechnology products currently
in use or under development and their
applications; it reviews estimates of the
biotechnology industry’s size and scope;
and it gives some details on where
biotechnology companies are active in
the U.S., with emphasis on the industry’s
presence in the states of the Third
Federal Reserve District: Pennsylvania,
New Jersey, and Delaware.
THE RISE OF BIOTECHNOLOGY
Yeast has been a component of
baking and fermenting throughout
recorded history, and its use is probably
older than the written record. Vaccina-
tion against the smallpox virus was
introduced in the 18th century, long
before the details of cell structure and
action were known. But it was James
Watson and Francis Crick’s discovery of
the structure of DNA, the molecule
that carries genetic information, in 1953
that ushered in the modern era of
biotechnology.  Since then, the science
of genetics and its technological
applications have advanced rapidly. In
1961, the first biopesticide was devel-
oped to protect important agricultural
crops. In 1973, came the first alteration
of a DNA molecule, the biotech process
now referred to as recombinant DNA
technology. (See the Glossary of
Biotechnology Terms.) In 1982, the U.S.
Food and Drug Administration
approved the first drug developed by
biotechnology: human insulin produced
in genetically modified bacteria.  In
1989, cotton was genetically modified to
protect it against insects, and corn
followed the next year.  The first animal
cloned from an adult cell, Dolly the
sheep, arrived in 1997. Advances in
biotechnology are accelerating, and the
scope of biotechnology’s applications is
widening. More than 100 biotechnology
drugs and vaccines are used today in
the United States; agricultural applica-
tions of biotechnology are extensive;
and industrial uses are growing.
MAJOR BIOTECHNOLOGY
PRODUCTS
Recent advances in under-
standing the chemistry of cells and
biological molecules, such as DNA and
proteins, have been extensive.  This
growing knowledge has led to a variety
of technologies and products that have
provided benefits to human health and  Business Review  Q4  2002   7 www.phil.frb.org
Glossary of Biotechnology Terms
Antibody – a protein produced in the body in response to for-
eign proteins entering the body, as in infections.  Antibodies
chemically deactivate the foreign protein to protect the body.
Antigen – a substance that induces the body’s immune re-
sponse system to produce an antibody.
Assay – a scientific test for measuring biological response to a
drug or other treatments.
Autoimmune disease – a disease in which the body produces
antibodies that attack its own tissues.
Biocatalyst – an enzyme that causes or facilitates a biochemi-
cal reaction.
Biochemical – a chemical resulting from a chemical reaction
in a living organism.
Bioinformatics – the collection and analysis of data by com-
puters for use in biological research; often used in genomic
research.
Biologicals – medicines made from living organisms or their
products; also known as biological drugs.  Examples include
vaccines and serums.
Chromosome – components of a cell nucleus that carry genes,
made up of DNA and protein.
Clone – genes, cells, or organisms that are derived from a single
common gene, cell, or organism and that are genetically iden-
tical.
DNA (Deoxyribonucleic acid) – the molecule that carries
genetic information.
DNA probe – a piece of nucleic acid that has been labeled
with a radioactive isotope and used to locate a particular gene
on a DNA molecule.
Diagnostic – a product used for the diagnosis of a medical
condition.  Monoclonal antibodies and DNA probes are bio-
technological diagnostics.
Enzyme – a protein that controls chemical reactions in living
organisms.
Expression – manifestation of a characteristic that is based on
a gene.  Also used to refer to the production of a protein by a
gene.
Gene – a segment of a chromosome that has a specific heredi-
tary function.  Genes control the production of proteins and
regulate other molecular functions in living organisms.
Gene mapping – determining the location of genes on a chro-
mosome.
Gene sequencing – determining the specific order of the nucle-
otide bases (constituent parts of the DNA molecule) in a strand
of DNA.
Gene therapy – the replacement of a defective gene.
Genetic modification – altering the genetic material of living
cells to make them capable of producing new substances or
performing new functions.
Genome – the complete chromosome set in the cell nucleus.
Genomics – the study of gene function.
Monoclonal antibody – an antibody derived from one clone
of cells that reacts to only one antigen.
Protein – a molecule made up of amino acids (acids contain-
ing one nitrogen and two hydrogen atoms in combination).
Proteins carry out the chemical processes involved in genetic
activity and other cell functions.
Proteome – the total collection of proteins in a cell, different
for different types of cells.
Proteomics – the study of a proteome and the functioning of
proteins.
Recombinant DNA – the process of making new DNA by
combining DNA components from different organisms; used
in genetic modification and gene therapy.
Stem cell – a cell that can grow into any specific type of cell in
a living organism.  Embryos develop from stem cells.
applications of economic significance to
agriculture and other industries. (For a
brief description of major biotechnolo-
gies, see Biotechnologies and Their
Applications.)
Biotech Drugs. There were
over 100 biotech drug products and
vaccines available in 2000.1 Current
biotech medicines include important
treatments for anemia, cystic fibrosis,
growth deficiency, hemophilia, hepatitis,
transplant rejection, and leukemia and
other cancers.  Biotech products are also
used for several diagnostic procedures.
Biotech drugs have been introduced at
an increasing rate, especially since the
mid-1990s.  Approvals of new biotech
drugs and new uses for existing biotech
1 See Biotechnology Industry Organization,
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Cell culture technology is the growing of cells outside the living organism in which they
develop naturally. Applications of this technology include growing cells on which to test new
medicines, growing cells to replace dead or malfunctioning cells in human organs, and mass
producing natural substances of medicinal value.
Cloning is the reproduction of molecules, cells, plants, or animals that are genetically identical
to their source. Cloning gained notoriety in 1997 when scientists cloned a sheep from an adult
sheep cell. Before that, animal cloning had been done with embryo cells. Monoclonal antibody
production and much of cell culture technology are based on cloning. Cloning is used in
livestock breeding, pharmaceutical manufacturing, and modification of agriculturally important
plants.  In addition, cloning is a basic part of other biotechnologies.
Genetic modification technology, sometimes called genetic engineering or recombinant
DNA technology, is the insertion of genetic material from one organism into the genetic
material of another organism.  In a sense, this technology is a more specific and direct
approach to the same ends as selective breeding in that desirable traits, coded in genetic
material, are transferred from one organism to another. Subsequent generations of this organism
will have these traits. Genetic modification technology is already widely used in agriculture.
Other uses of this technology include production of medicines and vaccines, treatment of
genetic diseases, and nutritional enhancement of foods.
Monoclonal antibody technology develops antibodies from cloned cells that can be used to
identify and treat antigens that infect humans, animals, and plants. Because antibodies are
very specific in their action, monoclonal antibody technology encompasses an extensive field
of research. One of the more important applications of this technology is cancer treatment
and vaccines, such as the biotech vaccine against hepatitis B.  Another important use is the
diagnosis of infectious diseases in humans, animals, and plants.  Monoclonal antibody
technology is also used to locate environmental pollutants and to detect harmful
microorganisms in food.
Protein engineering technology is used to modify proteins, which are constituents of genes
and enzymes. Proteins are the chemical substances through which much genetic and cellular
activity occurs, so there is a growing research effort to understand and manipulate proteins.
Currently there are several biotech drugs based on protein chemistry for treatment of anemia,
cystic fibrosis, hemophilia, leukemia, and some cancers.  Besides their functions in living
organisms, enzymes are also used as biocatalysts to improve the efficiency of production
processes for chemicals, textiles, pharmaceuticals, pulp and paper, food, and animal feeds.
Biotechnologies and Their Applications
drugs generally increased from 1993 to
2001.2 In that same period — mid-1990s
to the present — the number of new
drug and new use approvals annually for
nonbiotech drugs rose, but not by as
much as biotech drugs. Thus, in the past
several years, biotech drugs have
become a larger percentage of the
annual number of total new drug and
new use approvals, increasing from 6
percent in 1993 to 15 percent in 2001
(Figure 1).
In 2000, the latest year for
which data are available, 369 biotech
medicines were undergoing clinical
trials.3 Clinical trials usually come at
around the mid-point in the drug
development process, about eight years
after research to discover a specific new
drug begins and about seven years
before FDA approval.  Most new biotech
drugs currently being tested are
intended for cancer treatment (175
drugs). Other therapeutic categories
with a large number of biotech drugs in
the clinical trial phase are infectious
diseases (39), neurological disorders
(28), heart disease (26), and respiratory
diseases (22).
Agricultural Uses. Biotech-
nology has become an important aspect
of plant agriculture in a short time. The
most important use of genetic modifica-
tion in plant agriculture is herbicide
tolerance.  In this process, the genetic
composition of plants is altered to make
them resistant to damage from the
chemical herbicides used to kill weeds
in the fields where they are grown. In
this way, crop losses from herbicides are
reduced and yields are increased. When
plants are made resistant to more lethal
herbicides, fewer applications of
herbicide can be used, reducing both
farmers’ production costs and environ-
mental damage.
The second major use of
genetically modified crops is insect
resistance. This process involves taking
genetic material from naturally occur-
ring organisms that are lethal to insects
and inserting it into plants. When the
genetic insecticide from a naturally
occurring bacterium is inserted in the
genetic makeup of plants, the insects
that feed on them are killed before they
destroy the plant.4 This obviates the
need for chemical insecticides, thereby
protecting crops more efficiently and
reducing the threat of poisoning animals
and humans.
4 The most common source in this application
is genetic material from Bacillus thuringiensis
(Bt), a naturally occurring bacterium lethal
to insects.
2 Since 1993 the Food and Drug Administra-
tion has counted new use approvals (formally
called “efficacy supplements”) separately from
new drug approvals.
3 See Pharmaceutical Research and
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FIGURE 1
New Drug and New Use Approvals
Source: FDA Center for Drug Evaluation and Research; Biotechnology Industry Association
FIGURE 2
Global Area of Transgenic Crops
Source: International Service for the Acquisition of Agri-Biotech Applications
Agriculture has also made use
of genetically modified seeds, which first
became commercially available in 1996.
Between 1996 and 2001, the area
planted with genetically modified crops
worldwide increased 30 times (Figure
2).  Although the share of the world’s
total cropland planted with genetically
modified seeds is small — approximately
3 percent — genetically modified seeds
are a large share of the acreage of some
important food crops.  Of the four main
crops — soybean, cotton, canola, and
maize (corn) — for which genetically
modified seeds are used, the portion
planted with genetically modified seeds
comprises 19 percent of the world’s total
acreage planted with those crops (Figure
3).
The use of transgenic crops
continues to grow, and American
farmers have been the world leaders in
adopting their use.5 Recently, the U.S.
Department of Agriculture estimated
that American farmers will increase
their plantings of genetically modified
corn, soybeans, and cotton this year to
32 percent, 74 percent, and 71 percent,
respectively, of the total acreage for
these crops.  Although farmers’ interest
in using transgenic crops appears to be
increasing, there is growing public
concern about possible harm to human
health and unintended effects on
naturally occurring plants through
uncontrolled dissemination of transgenic
agricultural products.  Many national
governments have begun to regulate
transgenic food products, and an effort
is under way through the United
Nations to establish international rules
for identifying, packaging, and handling
genetically modified living organisms.6
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5 “Transgenic” means carrying genes
transferred from another species or breed.
Data on U.S. farmers’ use of transgenic seeds
are from the U.S. Department of Agriculture
crop and planting reports (U.S. Department
of Agriculture, 2001a, 2002).
6 See United Nations, 2000.10   Q4  2002 Business Review www.phil.frb.org
FIGURE 3
Transgenic Crops vs. Total (2001)
Source: International Service for the Acquisition of Agri-Biotech Applications
 Industrial Applications. In
industry, the most prevalent biotech
products are enzymes used in chemical
processes.  There is a wide variety of
enzymes, each acting on different
compounds.  The most commonly used
enzymes in industry break down protein,
cellulose, fats, and starches.  These
enzymes are used in detergents and
industrial cleaners, in baking and
brewing, and in the production of




firms fall mainly within the pharmaceu-
tical and the physical and biological
research industries.  There is no
industrial classification for biotechnol-
ogy, as such.  Furthermore, educational
institutions and hospitals conduct
biotech research, and chemical firms
carry out research as well, especially for













agriculture. Consequently, data on the
economic scale of biotechnology are
difficult to obtain.  Information on
revenue, employment, and other aspects
of the biotechnology industry must be
obtained primarily from industry sources,
such as the Biotechnology Industry
Association, and individual companies.
Biotechnology companies had
sales of $18 billion in 2001, according to
the Biotechnology Industry Associa-
tion.7  The industry’s revenues are still
small compared with the overall U.S.
pharmaceutical industry, which had
estimated worldwide sales of around
$180 billion in 2001, but they have been
growing rapidly.8 Aggregate sales
revenue of biotechnology companies has
increased more than 200 percent since
1993, compared with an increase of 137
percent since then in sales of the overall
U.S. pharmaceutical industry.  More-
over, sales figures of biotech firms do not
represent the true importance of
biotechnology. Biotechnology research
and development (R&D) is an impor-
tant and growing part of larger, more
diversified firms in the medical,
pharmaceutical, agricultural, and
industrial sectors.
According to the Biotechnol-
ogy Industry Association, there are
about 1400 biotechnology companies in
the U.S., of which approximately 340 are
publicly held.  Many, but not all, of the
companies are classified in the pharma-
ceuticals industry.  Employment in the
biotech industry is estimated at 174,000
jobs. Total employment in the pharma-
ceutical manufacturing industry is
214,000.9  These numbers are not strictly
comparable because biotech firms and
employment in those firms encompass
not just biotech-based drug companies
but also other nondrug companies
related to biotech, such as research
firms, universities, and firms providing
services to the biotech industry. Outside
of specialized biotech firms, many people
are employed in biotechnology research
and the production of biotechnology
products in large firms, primarily major
pharmaceutical companies, and in
chemical companies that produce
agricultural products, such as seeds and
pesticides.
Capital invested in biotechnol-
ogy firms can also give us a measure of
the industry’s size.  This measure is
especially relevant for this industry
because the industry is new and many
firms are spending on R&D, without
significant sales.  Estimates of the funds
raised by biotech firms approached $40
7 Data on biotech sales, revenue, and
employment are from the Biotechnology
Industry Association, 2002a.
8 Data on the overall pharmaceutical industry
are from Pharmaceutical Research and
Manufacturers of America, 2001. 9 U.S. Bureau of the Census, 2002.  Business Review  Q4  2002   11 www.phil.frb.org
billion in 2000, the recent peak year,
with approximately $25 billion of that
coming from public stock and debt
offerings, such as bonds.10  In compari-
son, total funds raised via stock and debt
offerings by all U.S. public corporations
in that year were $944 billion.11  As the
stock market weakened subsequently,
biotech financing shrank along with the
overall decline — to about $11 billion in
2001.12
Biotechnology firms rely on a
variety of financing methods (Figure 4).
Public financing comes primarily from
initial public offerings (IPOs) of stock
and follow-on stock offerings.  Publicly
held biotech firms also use loans,
warrants, debt offerings, and private
placements to finance their work.13
Lesser amounts are raised by companies
that have not yet tapped the public
market.  Financing for these companies
comes primarily in the form of venture
capital and equity buys from partners,
often large pharmaceutical companies.
Although the amount of money raised
in this way is lower than publicly raised
funds, it is critical for biotech firms in
the early stages of R&D, when the need
for financing is great but the ability to
attract investment in the market is
slight.
Venture capital was around 10
percent of total biotech industry funding
in 2000, according to industry sources.
Although venture capital accounts for a
small portion of the industry’s funding,
FIGURE 4
Biotech Industry Funding (2000)












10 See Biotechnology Industry Association,
2001.
11 See Board of Governors, 2001.
12 See Burrill and Company.
13 A warrant is a company-issued certificate
that represents an option to buy a certain
number of stock shares at a specific price
before a predetermined date. A private
placement is a large block of securities offered
for sale to an institutional investor or a
financial institution through private
negotiations.
venture capitalists serve important
functions for young biotech companies
by providing management expertise and
preparing the firms for their initial public
offerings.14 Nationally, venture capital
invested in biotechnology companies
was 6 percent of total venture capital
investments in 2001.
In our tri-state region, the
proportion of venture capital going to
biotechnology has been greater than in
the nation as a whole. In New Jersey,
biotechnology venture capital was 19
percent of the state total; in Pennsylva-
nia, it was 15 percent (see the Table).15
Another common feature of
early-stage biotech financing is collabo-
ration with a major pharmaceutical
company.  The larger firm in a collabora-
tive agreement often provides R&D
support, production facilities, and
marketing arrangements for the biotech
firm.  The larger firm recoups its
investment through marketing rights
under a license agreement.  Although
funds provided through collaborative
agreements are not a large portion of the
biotech industry’s total capitalization,
the money is an early source of much
needed capital, and the interest of a
large pharmaceutical firm can be an
important signal to the markets about
the biotech startup’s prospects.
Once beyond the early
financing stage, biotech firms rely on
initial public offerings of stock, loans,
private placements, and other forms of
capital.  These more traditional forms of
corporate financing have recently
become more available to biotech firms
than they were in the past.  According
to industry analysts, by the end of the
1990s, a number of large, well-capital-
14 See the article by Mitchell Berlin.
15 No amounts of venture capital for biotech
firms were reported for Delaware.12   Q4  2002 Business Review www.phil.frb.org




New Jersey 268 18.9




















New Mexico 2 9.0
Alabama 1 1.4
TABLE
Biotech Venture Capital Invested (2001)
ized biotech firms had emerged, and
these firms now have the financial
resources to fund their development




concentrated in places that are popu-
larly considered high-tech areas.
According to Ernst & Young, there are
approximately 1460 major biotech firms
in the country, concentrated in a few
states. A little over 400 are in California,
just over 200 in Massachusetts, nearly
100 in Maryland, about 90 in North
Carolina, and approximately 70 each in
Pennsylvania, New Jersey, and New
York.  Other leading states are Washing-
ton, Georgia, and Texas (around 40
companies each) and Florida and
Colorado (approximately 30 companies
each).  These 12 make up the top
biotech states in Ernst & Young’s tally
(Figure 5).
The geographic distribution of
research efforts shows a cluster pattern
as well. A few biotech centers dominate
the rankings of metropolitan areas in
terms of number of biotech patents
granted between 1975 and 1999. The
New York consolidated metropolitan
area is first with nearly 12,000 patents,
followed by San Francisco and Philadel-
phia with over 5000 each. Next comes
Boston with over 3000, and Washington,
D.C. and Chicago with over 2000 each.
Only six other metropolitan areas have
more than 1000 biotech patents each.16
The data for the New York area reflect
much of the biotech activity that takes
place among the many pharmaceutical
firms located in the New Jersey portion
of New York’s metropolitan area.
Likewise, a substantial share of biotech
activity in the Philadelphia area takes
place among the chemical firms located
in the Delaware portion of the metro-
politan area as well as among biotech
and pharmaceutical firms in the
Pennsylvania portion.
Because the biotechnology
industry is growing rapidly and because
many biotech firms are small, any count
of their numbers is likely to be an
underestimate.  Furthermore, universi-
ties and other nonprofit organizations as
Source: PricewaterhouseCoopers/Venture Economics/National Venture Capital
Association Money Tree Survey
16 Data on patents issued 1975-99 are from the
paper by Joseph Cortright and Heike Mayer.
The patent data used include patent classes
for drugs, molecular biology, and multicellular
living organisms. The patent class for drugs
includes biotech and nonbiotech drugs.
When only data from the patent classes for
molecular biology and multicellular living
organisms are used, as a more restricted
classification of biotech, the geographic
distribution of patents is substantially similar
among the top six metropolitan areas, but
there is some reordering within the group and
two areas are displaced by others not in the
first grouping.  Using the restricted
classification the order is Boston, San
Francisco, San Diego, Raleigh, New York, and
Philadelphia.  The areas moving down,
including Philadelphia, have proportionately
more of their biotech research devoted to
discovering new drugs compared with the
areas moving up or retaining their original
ranking.  Business Review  Q4  2002   13 www.phil.frb.org
FIGURE 5
Leading Biotech States (2001)
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well as large pharmaceutical firms
undertake biotech research. These
factors should be taken into account to
accurately assess the biotechnology
industry nationally and in the region.
BIOTECHNOLOGY IN THE
REGION
Biotechnology is well repre-
sented in the three states of the Third
District.  As noted above, data from
Ernst & Young place New Jersey and
Pennsylvania among the top biotech
states in terms of the number of major
biotech firms located in the two states.
Both states, as well as Delaware, figure
prominently in biotech patenting. State
biotechnology associations are active in
Pennsylvania and New Jersey, and
membership in these associations takes
in more firms and institutions than are
included in Ernst & Young’s count.
Within the region, biotech firms tend to
cluster in locations that have established
bases of pharmaceutical firms and life
sciences facilities, such as research
universities and medical centers (see the
map).
In New Jersey, biotechnology
firms have sprouted in an area where
many of the world’s largest pharmaceu-
tical firms have been well established.
Universities in the state are also engaged
in biotech research. Biotech and other
life sciences firms are concentrated in
the middle and northern parts of the
state.
In Pennsylvania, the Philadel-
phia metropolitan area is a biotech hub,
but there are also biotech clusters in
central Pennsylvania, centered on
Pennsylvania State University, and in
the Pittsburgh area, the location of
Carnegie Mellon University and the
University of Pittsburgh, which have
active biotech research programs.  In the
Philadelphia area, the life sciences are
represented by major pharmaceutical
firms as well as educational institutions
with health and medicine programs,
MAP
Biotech Firms
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such as the University of Pennsylvania,
Thomas Jefferson University, University
of the Sciences, and Drexel University/
MCP Hahnemann University.
Delaware should not go
unmentioned; the state’s traditional
chemical industry is evolving from
producing basic chemicals to more
specialized products, including pharma-
ceuticals.  Besides Wilmington, where
chemical and pharmaceutical compa-
nies have a well-established presence,
the New Castle area is developing as a
center for biotech firms.
Biotechnology firms and other
establishments engaged in biotech
research in the region are using all the
major technologies outlined earlier.
They are applying these technologies in
human health, agriculture, and
environmental protection.  The region’s
firms and other institutions have
developed expertise in several major
technologies.  A partial list includes
genomics, proteomics (the study of the
functioning of genes and proteins,
respectively), monoclonal antibody
production, implants and tissue substi-
tutes, combinatorial chemistry, gene
therapy, genetic modification of plants,
and DNA sequencing.
In addition to these relatively
more established technologies, firms and
institutions in the region are taking the
lead in newer biotechnologies.17  One of
these is bioinformatics, the use of
computer database management and
computer simulation to model cells and
biological molecules. A broader use of
bioinformatics is to analyze data from
different research and testing sources in
an integrated way. Another new
biotechnology in which the region’s
institutions are at the forefront is
biosensor and bio-nanotechnolgy, which
combine information about cellular
activity gained by biotechnolgy with
nano-scale electronics. Some applica-
tions of this technology are monitoring
single-cell activity electronically,
analyzing blood components in real
time, and testing food products for
safety and nutritional value.
Recognizing the economic
potential of biotechnology, educational
institutions and state and local govern-
ments have joined with biotechnology
companies and industry groups to
promote the industry in their areas.
Sixteen states are using funds from the
tobacco industry case to support
bioscience research and development,
and 10 states have formulated biotech-
nology or life sciences strategic plans.18
Important aspects of joint public and
private efforts to facilitate the develop-
ment of biotech firms will be early-stage
funding, academic and industry
cooperation, and alliances between
established large firms and startups, all of
which have been key elements in the
early growth of the biotech industry.19
Pennsylvania has sketched out
an ambitious program to support the
biotechnology industry in the state,
using funds from the tobacco settle-
ment.  The state is establishing a life
sciences venture fund and creating
three “biotech greenhouses.” One will
be located in Philadelphia and one in
Pittsburgh; the third, in central Pennsyl-
vania, will coordinate the biotechnology
efforts of Pennsylvania State University,
Penn State Milton S. Hershey Medical
Center, Penn State College of Medicine,
and Lehigh University.  The green-
houses will be consortiums of educa-
tional institutions, medical research
establishments, private companies, and
industry groups. They will provide
venture capital, promote commercializa-
tion of technology developed at
universities, operate business incubators
for biotechnology startups, and market
their areas’ biotechnology resources.
The goal of the greenhouses is to
commercialize the biotech expertise of
the educational institutions and start-up
companies in their areas.20
In New Jersey, state govern-
ment agencies, universities, and the
Biotechnology Council of New Jersey,
an industry association, have formed the
New Jersey Coalition for Biotechnology
to promote the state’s biotechnology
industry and facilitate pharmaceutical
research.  In recent years, the state’s
Commission on Science and Technology
has provided start-up funds for several
biotechnology research facilities,
including the Biotechnology Center for
Agriculture and the Environment and
the Center for Advanced Food
Technology at Rutgers University/Cook
College, the Center for Advanced
Biotechnology and Medicine at the
University of Medicine and Dentistry of
The region’s firms and other institutions have
developed expertise in several major
technologies.
17 See the reports of the three Pennsylvania
biotech greenhouses (Biotechnology
Greenhouse Corporation of Southeastern
Pennsylvania, 2001; Pittsburgh Life Sciences
Greenhouse, 2002; Life Sciences Greenhouse
of Central Pennsylvania, 2002); Biotechnology
Council of New Jersey, 2001; Delaware
Biotechnology Institute, 2002.
18 See the paper from Battelle Memorial
Institute.
19 See the article by Martha Prevezer.
20 The Philadelphia greenhouse will focus on
research in genomics, proteomics, monoclonal
antibodies, diagnostics, implants, and
bioinformatics.  The Pittsburgh greenhouse
will conduct research on proteomics,
bioinformatics, gene therapy, diagnostics, and
bio-nanotechnology.  The central Pennsylva-
nia greenhouse will focus on biotech drug
design and delivery techniques, implants, and
bio-nanofabrication.  Business Review  Q4  2002   15 www.phil.frb.org
New Jersey and Rutgers University, and
the Lewis Thomas Molecular Biology
Laboratory at Princeton University.  In
other forms of state support, the New
Jersey state pension fund has begun
making investments in biotechnology
firms, and the state has enacted several
tax credits that benefit biotech and
other high-tech companies.
In Delaware, a consortium of
state government, higher education
institutions, and biotech companies was
formed in 1999. This Delaware Biotech-
nology Institute opened a research
facility in 2001 in the Delaware
Technology Park, adjacent to the
University of Delaware’s campus in
Newark. The institute provides research
facilities and offers educational
programs in the sciences and in the
business aspects of biotechnology. The
institute focuses on biotech applications
in agriculture, biomaterials, human
health, and marine ecosystems. In
addition to funding the institute, the
state of Delaware invests in biotech
firms through several venture capital
funds. Delaware also offers tax credits to
businesses that engage in R&D in
certain fields, including biological
sciences, beyond the credits available for




Most industry analysts expect
strong growth in the biotechnology
industry in terms of both number of new
products and revenue.  Cancer has
emerged as a major target of biotechno-
logical research. Around half of the 500
drugs expected to be in development
during 2002 will be aimed at treating a
range of cancers.21 Developments in
proteomics are stimulating much of this
work.
Another stimulus is the
national effort to develop and stockpile
vaccines and medicines to cope with
biological terrorism. Short-term efforts to
defend against bioterrorism are focused
on developing vaccines and antibiotics
to treat such diseases as anthrax, plague,
and smallpox.22 But longer term, there
will be an increased effort to develop
means of detecting and responding to
bioterror attacks based on DNA testing
and bio-nanotechnology. In an effort to
speed up the testing process, biotech
firms will develop genetically appropriate
organisms for drug trials. In addition,
decoding the genomes of disease-
causing bacteria and viruses will receive
greater emphasis.
Some public policy issues might
affect biotech R&D in medicine, chiefly
stem cell cloning and patent protection
for biotechnology products. The
biotechnology industry generally
supports the current voluntary morato-
rium on attempts to clone a complete
human being, but it opposes total
restriction on cloning human stem
cells.23 With respect to patenting,
Congress is considering changes to U.S.
patent law that will promote biotech
research on a wide scale while providing
effective patent protection to developers
of new biotech products. The biotech-
nology industry favors maintaining and
strengthening patent protection of
modified genes and other biotechnologi-
cal products. Areas where biotech
patent protection might be vulnerable,
according to industry organizations, are
generic biotech products and the timing
of patent protection during the drug
approval process.24 Specifically, the
industry argues that the long lapse
between the application for a drug
approval and commercial introduction
of a drug reduces the amount of time
the patent protects the product once it is
on the market.
In agricultural biotechnology,
consumers’ attitudes toward genetically
modified foods might hinder further
development. To date, genetically
modified foods have gained acceptance
among U.S. consumers, but they have
been less well received in Europe.
Surveys indicate that when consumers
are aware of the desirable characteristics
possible through genetic modification,
they are more likely to have positive
attitudes toward genetically modified
foods.25 Some agriculture industry
analysts speculate that a dual market for
foods may develop, in which consumers
will tend to choose either genetically
modified foods or nonmodified foods.26
Such a development might ensure a
continuing market for genetically
modified foods, but the costs of segregat-
ing modified and nonmodified foods
from farm to table is currently estimated
to be almost prohibitively high. Working
in the opposite direction, however, is the
increasing effectiveness of genetic
modification in reducing food-produc-
tion costs.
With respect to the industry’s




industry in terms of
both number of new
products and revenue.
21 See Frank DiLorenzo’s Industry Surveys.
22 See Pharmaceutical Research and
Manufacturers of America, 2002.
23 See Biotechnology Industry Association,
2001.
24 See Biotechnology Industry Association,
2002b.
25 See U.S. Department of Agriculture, 2001b.
26 See the article by Nicholas
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Interest in the industry is growing
among venture capitalists, institutional
investors, and large pharmaceutical
firms.  Although early-stage investments
will still be important to young biotech
firms, more and more biotechnology
companies have amassed sufficient
capital and personnel to bring new drugs
to market without the need for alliances
with major pharmaceutical firms.  Thus,
an increasing number of biotech firms
will remain independent of pharmaceu-
tical companies as they expand from
research into manufacturing and
marketing.  At the same time, mergers
and alliances between biotech firms,
rather than between biotech and
pharmaceutical firms, are likely to
become more common.  Nonetheless,
major pharmaceutical firms are ex-
pected to retain an interest in alliances
with biotech companies in order to
ensure themselves of a continuing
stream of new products and to comple-
ment their own biotechnology research.
In agricultural biotechnology B R
there has been an increase in vertical
combinations of firms. For example,
chemical companies and other biotech
firms have merged with or acquired
seed companies to obtain sources of
seeds for modification and sales
channels for modified seeds. In addition,
high levels of research expenditure, the
need to protect intellectual property
rights, and increasing globalization of
the agriculture industry in general have
fostered increases in joint ventures,
licensing agreements, and strategic
alliances among biotech and traditional
agricultural firms.  These trends are
expected to continue.
SUMMARY
The biotechnology industry is
advancing rapidly in its ability to
develop new medicines, diagnostic
methods, and agricultural products.  It is
also growing as an industry.  Capital
investment in the industry is forecast to
increase sharply, and as more new
products are brought to market over the
next several years, the industry is
expected to experience strong revenue
growth. More companies as they grow
will add production and marketing to
their research and development efforts.
Nevertheless, rapid advances in the life
sciences that support commercial
applications of biotechnology will mean
that research remains a large and vital
activity for successful biotech firms.
In the region, the well-
established biotech presence should
continue to grow.  Public and private
efforts in the region to further stimulate
the industry are expanding.  Particularly
important, according to industry
analysts, is a strategy for taking research
discoveries on to successful product
launches.  This process of commercial-
ization is a focus of state government
and other efforts to encourage the
industry here. The region is a biotech-
nology wellspring, and private and
public interest in biotechnology in the
region should ensure its continued
success.  Business Review  Q4  2002   17 www.phil.frb.org
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